Genetic loss of D‐amino acid oxidase activity reverses schizophrenia‐like phenotypes in mice
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Reduced function of the N‐methyl‐d‐aspartate receptor (NMDAR) has been implicated in the pathophysiology of schizophrenia. The NMDAR contains a glycine binding site in its NR1 subunit that may be a useful target for the treatment of schizophrenia. In this study, we assessed the therapeutic potential of long‐term increases in the brain levels of the endogenous NMDAR glycine site agonist D‐serine, through the genetic inactivation of its catabolic enzyme D‐amino acid oxidase (DAO) in mice. The effects of eliminating DAO function were investigated in mice that display schizophrenia‐related behavioral deficits due to a mutation (Grin 1D481N) in the NR1 subunit that results in a reduction in NMDAR glycine affinity. Grin 1D481N mice show deficits in sociability, prolonged latent inhibition, enhanced startle reactivity and impaired spatial memory. The hypofunctional Dao 1G181R mutation elevated brain levels of D‐serine, but alone it did not affect performance in the behavioral measures. Compared to animals with only the Grin 1D481N mutation, mice with both the Dao1G181R and Grin 1D481N mutations displayed an improvement in social approach and spatial memory retention, as well as a reversal of abnormally persistent latent inhibition and a partial normalization of startle responses. Thus, an increased level of D‐serine resulting from decreased catalysis corrected the performance of mice with deficient NMDAR glycine site activation in behavioral tasks relevant to the negative and cognitive symptoms of schizophrenia. Diminished DAO activity and elevations in D‐serine may serve as an effective therapeutic intervention for the treatment of psychiatric symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Moy, S. S., Nadler, J. J., Perez, A., Barbaro, R. P., Johns, J. M., Magnuson, T. R., Piven, J., & Crawley, J. N. (2004) · Genes, Brain and Behavior · doi:10.1111/j.1601-1848.2004.00076.x · Cited by 1,522 · cited 1×
“Social affiliation The social affiliation task was conducted similarly to previously described studies (Labrie et al. 2008c; Moy et al. 2004), using a clear Plexiglas box (61.”
MethodGeyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Glia-Derived d-Serine Controls NMDA Receptor Activity and Synaptic Memory
Panatier, A., Theodosis, D. T., Mothet, J.-P., Touquet, B., Pollegioni, L., Poulain, D. A., & Oliet, S. H. R. (2006) · Cell · doi:10.1016/j.cell.2006.02.051 · Cited by 934
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917 · cited 3×
“tered in conjunction with conventional antipsychotics (Coyle 2006; Heresco-Levy et al. 2005; Tsai et al. 1998).”
BackgroundSchell, M. J., Molliver, M. E., & Snyder, S. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3948 · Cited by 832 · cited 2×
“2000), consistent with the inverse correlation between the distribution of DAO and D-serine in the central nervous system (CNS) (Moreno et al. 1999; Schell et al. 1995).”
BackgroundContribution of astrocytes to hippocampal long-term potentiation through release of d -serine
Yang, Y., Ge, W., Chen, Y., Zhang, Z., Shen, W., Wu, C., Poo, M., & Duan, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2431073100 · Cited by 533
Vasopressin V1b receptor knockout reduces aggressive behavior in male mice
Wersinger, S. R., Ginns, E. I., O'Carroll, A.-M., Lolait, S. J., & Young III, W. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001195 · Cited by 397
Sankoorikal, G. M. V., Kaercher, K. A., Boon, C. J., Lee, J. K., & Brodkin, E. S. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.026 · Cited by 231 · cited 1×
“Social deficits and their amelioration were specific to the test of sociability, which examines social approachand avoidance-related motivation (Sankoorikal et al. 2006).”
BackgroundDuffy, S., Labrie, V., & Roder, J. C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301486 · Cited by 173 · cited 4×
“Previously, exogenous D-serine treatments have been shown to fully reverse spatial deficits in the object discrimination and MWM task (Duffy et al. 2008; Labrie et al. 2008c).”
BackgroundMethodInfluentialSelf-citation
Cited by
Millan, M. J., Fone, K., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 347
The NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in Pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 285
Balu, D. T., Li, Y., Puhl, M. D., Benneyworth, M. A., Basu, A. C., Takagi, S., Bolshakov, V. Y., & Coyle, J. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304308110 · Cited by 217
The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond
Balu, D. T., & Coyle, J. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.004 · Cited by 208
Translating Glutamate: From Pathophysiology to Treatment
Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002804 · Cited by 168
Metadata
- Authors
- Labrie, V., Wang, W., Barger, S. W., Baker, G. B., & Roder, J. C.
- Venue
- Genes, Brain and Behavior
- Publisher
- Wiley
- Published
- 2010-01-28
- Volume
- 9
- Issue
- 1
- Pages
- 11-25
- ISSN
- 1601-183X (ISSN-L)
- 1601-1848
- OpenAlex
- W2066578437
- Cited by
- 55
- References
- 10
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.